Hep C and HIV among injecting drug users in London are higher than expected

Levels of hepatitis C virus and HIV among injecting drug users in London are higher than expected, according to a study published online by the BMJ.

During the 1990s, the prevalence of hepatitis C virus and HIV among this high risk group was relatively low compared with other countries. However, targets to prevent bloodborne viruses have been absent from the UK government's drug strategy in recent years.

In 2001, 428 new injecting drug users, mainly from London, completed questionnaires and provided samples to test for antibodies to hepatitis C virus and HIV.

Incidence of hepatitis C virus was high (41.8 cases per 100 person years) and of HIV was higher than expected (3.4 cases per 100 person years). These figures are supported by ongoing surveillance data, and suggest that transmission may have recently increased, say the authors.

Possible explanations for the rise include changes in patterns of injecting drug use and injecting risk behaviour in newer drug users than those injecting in the early to mid-1990s. In addition, there may have been increases in the number of injecting drug users over and above any increase in protective measures.

The authors argue that current drug policy is failing to protect this high risk group from bloodborne viruses. Innovative strategies are required to change behaviour and to deliver health education messages and harm reduction strategies early enough to make a difference, they conclude.

Click here to view full paper

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New national guidelines for anal cancer prevention in HIV patients based on UCSF research